This article has already been saved in your Saved Items
BDX
-1.65%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
SYK
-0.44%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
OPK
+1.20%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
PRAH
0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
OPKO Health, Inc. (NASDAQ:OPK) recently announced that its subsidiary — BioReference Laboratories — has collaborated with the state of New Jersey to provide coronavirus (COVID-19) testing across the state.
Notably, BioReference Laboratories will initially provide testing for facilities at Burlington, Essex, Hudson, Ocean and Union Counties.
For investors’ notice, BioReference Laboratories provides the detection, diagnosis, evaluation, monitoring and treatment of diseases. Hence, the latest move is likely to boost OPKO’s foothold in the global infectious disease diagnostics market.
More on the News
It is encouraging to note that given the widespread COVID-19 outbreak, OPKO’s BioReference Laboratories is currently accepting specimens for COVID-19 testing from healthcare providers, clinics and health systems throughout the United States.
Moreover, BioReference Laboratories also awaits an emergency use authorization (EUA) for its COVID-19 test from the FDA.
Market Prospects
A report by MarketsandMarkets projects the global infectious disease diagnostics market to reach a worth of $19.35 billion in 2022, at a CAGR of 5.6%.
Hence, the latest development has been a well-timed one for OPKO.
COVID-19 Wreaks Havoc
The COVID-19 pandemic has devastated the world. Notably, the United States is currently witnessing 35,070 cases, with the death toll rising to 458.
Given this grim backdrop, U.S. MedTech players are trying to ramp up testing to check the spread of the pandemic.
For instance, Becton, Dickinson and Company (NYSE:BDX) has recently announced the submission of EUA requests to the FDA for diagnostic tests. Notably, the tests, if authorized, would increase the potential capacity for COVID-19 screening by 1,000 per day. That’s not all. The company has also announced the receipt of the CE mark for the VIASURE SARS-CoV-2 real-time test adapted for the BD MAX System. Notably, the test, used to detect COVID-19, is now available to clinical laboratories.
Further, PRAH Health Sciences (NASDAQ:PRAH) recently announced the commercial availability of the COVID-19 Monitoring Program, a mobile app that allows employers, payers, providers and health systems to track the health and wellbeing of individuals.
Price Performance
Over the past year, shares of this Zacks Rank #3 (Hold) company have plunged 44.4% compared with the industry’s 24.9% decline.
A Key Pick
A better-ranked stock in the broader medical space is Stryker Corporation (NYSE:SYK) .
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, SherazMian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
Shares of Alibaba (NYSE:BABA) are on a tear to start off 2025. The consumer discretionary and tech stock is up by 52% this year as of the Feb. 25 close. The company’s cloud...
Every investor should know the term CEP, or customer engagement platform, because it is central to businesses' use of AI. CEPs provide software services to connect and communicate...
As markets try to look through the blizzard of policy changes flowing out of Washington, the crowd has shifted its preferences considerably in recent weeks based on a sector lens....
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrichthe conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
Only English comments will be allowed.
Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.